Suppr超能文献

哌啶衍生物作为新型人类热休克蛋白70抑制剂用于治疗耐药肿瘤的设计与合成

Design and synthesis of piperidine derivatives as novel human heat shock protein 70 inhibitors for the treatment of drug-resistant tumors.

作者信息

Zeng Yanqun, Cao Ruiyuan, Zhang Tianhong, Li Song, Zhong Wu

机构信息

Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China; Laboratory of Computer-Aided Drug Design and Discovery, Beijing Institute of Pharmacology and Toxicology, 27 Taiping Rd., Beijing, 100850, China.

Laboratory of Computer-Aided Drug Design and Discovery, Beijing Institute of Pharmacology and Toxicology, 27 Taiping Rd., Beijing, 100850, China.

出版信息

Eur J Med Chem. 2015 Jun 5;97:19-31. doi: 10.1016/j.ejmech.2015.04.043. Epub 2015 Apr 21.

Abstract

HSP70 is a potential target for tumour treatment. HSP70 plays significant roles in several biological processes, including the regulation of apoptosis. In this study, piperidine derivatives were designed as novel HSP70 inhibitors based on virtual fragment screening performed in Dock 4.0, Discovery Studio 2.5 and SYBYL 6.9. A total of 67 novel piperidine derivatives were synthesized. Cell viability assays were performed in 16 cancer cell lines. The emphasis was placed on lapatinib-resistant breast cancer cells (BT/Lap(R)1.0, MDA-MB-361, SK/Lap(R)1.0, and MDA-MB-453). The compounds HSP70-36/37/40/43/46 significantly inhibited the proliferation of human breast cancer cells. Compound HSP70-36 inhibited the growth of BT474 and BT/Lap(R)1.0 cells with IC50 values of 1.41 μM and 1.47 μM, respectively. The binding affinity of HSP70-36/HSP70 was evaluated by surface plasmon resonance and yielded Kd values of 2.46 μM. The LD50 was 869.0 mgkg(-1). These data suggest that HSP70-36 may be a potential candidate compound for tumour treatment.

摘要

热休克蛋白70(HSP70)是肿瘤治疗的一个潜在靶点。HSP70在多个生物学过程中发挥重要作用,包括细胞凋亡的调控。在本研究中,基于在Dock 4.0、Discovery Studio 2.5和SYBYL 6.9中进行的虚拟片段筛选,设计了哌啶衍生物作为新型HSP70抑制剂。共合成了67种新型哌啶衍生物。在16种癌细胞系中进行了细胞活力测定。重点研究了拉帕替尼耐药的乳腺癌细胞(BT/Lap(R)1.0、MDA-MB-361、SK/Lap(R)1.0和MDA-MB-453)。化合物HSP70-36/37/40/43/46显著抑制人乳腺癌细胞的增殖。化合物HSP70-36抑制BT474和BT/Lap(R)1.0细胞的生长,IC50值分别为1.41 μM和1.47 μM。通过表面等离子体共振评估HSP70-36/HSP70的结合亲和力,得到的解离常数(Kd)值为2.46 μM。半数致死量(LD50)为869.0 mgkg(-1)。这些数据表明,HSP70-36可能是一种潜在的肿瘤治疗候选化合物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验